Communique from the Annual General Meeting of Scandion Oncology A/S

On May 29th, 2019, the Annual General Meeting of Scandion Oncology A/S (”Scandion Oncology” or the“Company”) was held. Below follows a summary of the established decisions. All decisions were taken with the required majority. 

The Board of Directors report on the Company’s business in the past year

The general meeting took note of the Board of Directors report on the Company’s activities in 2018.

Presentation of the audited annual report for 2018 for approval

The general meeting unanimously adopted the audited annual report for 2018.

Decision to transfer the deficit for next year

The general meeting decided to transfer the deficit to the next year.

Election of members to the Board of Directors

The general meeting decided to elect Peter Høngaard as new Board member and to re-elect Carl Borrebaeck, Thomas Feldthus and Christian Vinding Thomsen to the Board of Directors until the next Annual General Meeting.

Appointment of auditor

The general meeting decided that the Company’s current auditor, Deloitte is re-elected until the next Annual General Meeting.

The Board of Directors of

SCANDION ONCOLOGY A/S

For additional information regarding Scandion Oncology, please contact:

Nils Brünner, CEO

Phone: +45 26 14 47 08

E-mail: nb@scandiononcology.com 

www.scandiononcology.com

Scandion Oncology A/S is a biotechnology company founded in 2017 for the purpose of addressing and tackling one of the greatest challenges in modern oncology – the effective treatment of cancer which contains drug resistant cell clones or which has developed resistance to a previously prescribed cancer-fighting drug. In preclinical animal studies, the company’s leading candidate drug, SCO-101, was found to significantly enhance the efficacy of certain standard cancer treatments when given in combination. In addition SCO-101 restores chemotherapy sensitivity in in vitro grown resistant cancer cells. Scandion Oncology will in Q4 2019 initiate a clinical phase II study with SCO-101 in combination with chemotherapy. Scandion Oncology was listed on Spotlight, Sweden in November 2018.

About Us

Scandion Oncology A/S is a clinical stage II biotechnology company currently developing first-in-class, oral add-on drugs to existing market leading anti-cancer therapies. As add on to standard anti-cancer therapies, it introduces an effective treatment approach for cancer, which is or has become resistant to cancer-fighting drugs, offering the potential for better response rates, longer survival and improved quality of life. The first-in-class lead candidate, SCO-101, is currently in clinical Phase II. The Company is targeting cancer drug resistance in various treatment modalities including, chemotherapy, anti-hormonal therapy and immunotherapy. Scandion Oncology is listed on Nasdaq First North Growth Market Sweden. Ticker: SCOL.